B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma

B2adrenergic Receptor Gene Polymorphism in Bronchial Asthma: Relation to Disease Severity and Control

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03118869

Acronym

polymorphism

Enrollment

Registered

2017-04-18

Start date

2017-04-01

Completion date

2017-10-30

Last updated

2017-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Gene Abnormality

Keywords

Asthma, B2 adrenergic receptors, Polymorphism

Brief summary

The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance. The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Detailed description

Asthma is a complex disease and has a strong genetic component in its pathogenesis. So far, considerable efforts have been made to evaluate the association between genetic variants and asthma risk, and numerous genes have been identified as asthma Reporting Items susceptible genes. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection. The b2-adrenoceptor (b2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, Enhanced mucociliary clearance. The b2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes. There are three best known polymorphisms in the coding region of the b2AR gene that can modulate the function of the receptor.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* patients diagnosed as asthma according to GINA guideline 2016. * Allergic asthma

Exclusion criteria

* pneumonia * chronic cardiac, hepatic and renal diseases * pregnancy and lactation * malignancy

Design outcomes

Primary

Measure	Time frame	Description
To measure number of patient with homozygous and heterozygous B2AD gene polymorphisms with focus on Arg/Gly16 and Gln/Glu27 polymorphism	1 month	study of prevalence homozygote and heterozygote patients

Secondary

Measure	Time frame	Description
Number of patient with b2AR gene polymorphisms in different asthma severity and different response of treatment of asthma ( Arg/Gly16 and Gln/Glu27 polymorphism)	1 month	correlation between polymorphism and pulmonary function test and level of disease control

Countries

Egypt

Outcome results